A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Clinical trial NCT06016088 · COMPLETED

Trial details

NCT number: NCT06016088
Sponsor: Respirion Pharmaceuticals Pty Ltd
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cystic Fibrosis Lung Respiratory Infections, Recurrent, Chronic Pseudomonas Aeruginosa

Start date: 2024-04-01
Primary completion: 2026-04-15
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.